Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · September 05, 2022

Dapagliflozin and Prevention of Kidney Disease in Patients With Type 2 Diabetes

Diabetes Care


Additional Info

Diabetes Care
Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes-Post Hoc Analyses From the DECLARE-TIMI 58 Trial
Diabetes Care 2022 Aug 23;[EPub Ahead of Print], O Mosenzon, I Raz, SD Wiviott, M Schechter, EL Goodrich, I Yanuv, A Rozenberg, SA Murphy, TA Zelniker, AM Langkilde, IAM Gause-Nilsson, M Fredriksson, PA Johansson, JPH Wilding, DK McGuire, DL Bhatt, LA Leiter, A Cahn, JP Dwyer, HJL Heerspink, MS Sabatine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading